We would like to inform you proudly about the next E-learning Hepatoblastoma session (E-LEARNING section), recorded in Bologna in November 2012 and published in the SIOPEL site.

It deals with such important issues as: assessment of liver tumor resectability, selection of hepatic resection vs. transplantation, miscroscopic residue and cases discussion.

Please feel free to view it after logging in.

SIOPEL recommends the treatment strategy for Hepatoblastoma patients not entered into a clinical trial:

Standard Risk Tumours: 4 cycles of CISPLATIN preoperative chemotherapy followed by surgical resection and 2 post operative cycles of therapy.

High risk tumours: the preoperative dose intensive “superPLADO” arm of the SIOPEL 3 study (Zsiros et al 2010 J Clin Oncol 28:2584). We would also recommend consultation at the time of diagnosis with a specialist liver surgery/transplant service.

Very high risk tumours: These tumours are defined by the presence of metastatic disease (usually lung) or very low AFP (<100 ng/ml). They should be treated with the approach utilised in the SIOPEL4 protocol with dose-intensive weekly cisplatin/doxorubicin induction therapy. This is an experimental regimen with limited pilot data shortly to be published.

One will find details LINK